PharmAsia News

We've Moved

PharmAsia News has moved to a new enhanced Web platform.  For continued news and analysis related to Asia, please visit our new site at www.pharmasianews.com and sign up for a 30-day free trial.

Chi-Med CEO Christian Hogg: An Interview With PharmAsia News (Part 2 of 2)

Chi-Med CEO Christian Hogg sat down recently with PharmAsia News to discuss how traditional Chinese medicine (TCM) serves as both the foundation for Chi-Med’s success and as its platform for growth. Chi-Med is focused on researching, developing, manufacturing and selling pharmaceuticals, health supplements and other health care and personal care products derived from TCM and botanical ingredients.

Chi-Med CEO Christian Hogg: An Interview With PharmAsia News (Part 1 of 2)

Chi-Med CEO Christian Hogg sat down recently with PharmAsia News to discuss how traditional Chinese medicine (TCM) serves as both the foundation for Chi-Med’s success and as its platform for growth. Chi-Med is focused on researching, developing, manufacturing and selling pharmaceuticals, health supplements and other health care and personal care products derived from TCM and botanical ingredients.

Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

Daiichi Sankyo's head of U.S. operations Joe Pieroni sat down with "The Pink Sheet" DAILY recently at the firm's U.S. headquarters in Parsippany, N.J., to discuss the company's cardiovascular products and pipeline and how the Japanese pharma is looking to the U.S. market as a core growth driver. Pieroni was tapped to lead the newly formed U.S. subsidiary in 2005 following the merger of Daiichi and Sankyo. Previously, Mr. Pieroni had launched Sankyo's U.S. commercial operations, first as president of the Sankyo Parke-Davis joint venture and then as president of Sankyo Pharma Inc., a wholly owned U.S. subsidiary.

Beijing Med-Pharm Chief Financial Officer Fred Powell: An Interview With PharmAsia News (Part 2 of 2)

Powell sat down recently with PharmAsia News to discuss the challenges that Western pharmaceuticals companies face when entering the Chinese market, the opportunities presented by China's recent economic boom, and the ways pharmaceutical companies can best navigate the evolving Chinese landscape. [Editor's note: Part 1 of this interview ran June 12.]

Beijing Med-Pharm Chief Financial Officer Fred Powell: An Interview With PharmAsia News (Part 1 of 2)

Fred Powell is Chief Financial Officer for Beijing Med-Pharm Corp. (BMP), which offers end-to-end solutions - including pre-market entry analysis, clinical trial management, registration, marketing and distribution - to Western pharmaceutical companies interested in selling their products in China.

Exclusive Report: Pharma IP Rights At Risk In Asia

Rockville, Md. (April 9, 2007) PharmAsia News announces the publication of an exclusive report:  Pharma IP Rights At Risk In Asia.  The report examines the ongoing compulsory license dispute in Thailand, where the government recently issued compulsory licenses for brand name drugs manufactured by Abbott, Merck and Sanofi-Aventis.

This complimentary report is available to download at http://www.fdcreports.com/asia/.

Becton, Dickinson CEO Ed Ludwig: An Interview With “The Gray Sheet”

In addition to heading the $5 billion-plus revenue generating Becton, Dickinson, and Co. as CEO, Edward Ludwig is halfway through his two-year term as chairman of AdvaMed’s board of directors.

Astellas VP-Business Development Masaki Doi: An Interview With "The Pink Sheet" DAILY (Part 2 0f 2)

"The Pink Sheet" DAILY visited recently with Astellas Pharma VP-Business Development Masaki Doi at the company's headquarters in Tokyo to talk about the Japanese pharma's global licensing strategy and the changing paradigm of Japanese deal flow. This is the second of a two-part interview. (Part 1 was printed yesterday in PharmAsia News).

Astellas VP-Business Development Masaki Doi: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)

"The Pink Sheet" DAILY visited recently with Astellas Pharma VP-Business Development Masaki Doi at the company's headquarters in Tokyo to talk about the Japanese pharma's global licensing strategy and the changing paradigm of Japanese deal flow.